Low molecular weight heparin sodium (LMWH) is a low molecular weight amino glucan sulfate, which is a new anticoagulant. It is a short chain heparin preparation prepared by various depolymerization groups. It has anticoagulant, antithrombotic, anti-inflammatory, anti-tumor and inhibiting effects on glomerular mesangial cells and stromal hyperplasia. At present, the main drugs used in the market are sodium diheparin, enoxaparin sodium and natroheparin calcium, which are anticoagulant and antithrombotic drugs and are colorless or light yellow clear liquid.

　　Compared with standard heparin, low molecular weight heparin sodium has a strong effect of anti-coagulation factor XA. However, the effect of anticoagulation factor Ⅱa and inhibition of thrombin was very weak. Therefore, this product has strong antithrombotic effect and less bleeding complications. In addition, low molecular weight heparin sodium has fibrinolytic activity, which can dissolve fresh thrombi formed. It has antithrombotic effect on human body. At the usual dose, it does not cause significant changes in the total coagulation index, does not prolong the bleeding time, the possibility of thrombocytopenia is very small, and fibrinogen binding has no change.

　　Compared with standard heparin, low molecular weight heparin preparation has higher bioavailability, longer half-life and faster absorption by subcutaneous injection. Low molecular weight heparin sodium has obvious and lasting antithrombotic effect, and its antithrombotic activity is stronger than anticoagulant activity. Therefore, there is less risk of bleeding with antithrombotic effect.

　　Clinical use:

　　① Prevention of deep vein thrombosis and pulmonary embolism.

　　② To treat acute deep venous thrombosis.

　　③ In hemodialysis or hemofiltration, prevent thrombosis or blood coagulation in the cardiopulmonary bypass system.

　　④ Low molecular weight heparin sodium is suitable for the prevention and treatment of thrombosis after surgery.